TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06696508

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insitu Spatulation with Pre-Dismembering Ureteropelvic Angle Suturing during laparoscopic pyeloplasty
Description: After proper dissection of the PUJ, the anterior wall of the renal pelvis was incised.~The incision continued downwards and laterally towards the PUJ and the lateral aspect of the ureter.~In cases where crossing vessels were present, the pelvis with the PUJ and the uppermost part of the ureter were properly dissected from these vessels. This gave a wide room for pulling the pelvis upwards and gentle retraction of the crossing vessels allowing incision of the anterior wall of the pelvis and starting the spatulation of the PUJ. Spatulation could then continue to the upper ureter behind the properly dissected and retracted vessels.~After complete spatulation and before dismembering the PUJ, we made benefit of splinting the ureter in place; a Maryland grasper opened the lumen of the ureter and the first stitch was precisely placed from outside inwards at the proper angle of the ureteric spatulation using 5/0 Vicryl sutures.~The posterior wall of the PUJ and the pelvis was then dismembered

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic Laparoscopic Dismembered Pyeloplasty
Description: the PUJ was dismembered after proper dissection, the lateral aspect of the ureter was spatulated and the first stich was also placed in the spatulation angle from outside inwards. All these steps were done after the discontinuation of the ureter and the pelvis, losing the benefit of ureteric splinting and orientation
Study: NCT06696521

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention A- Telephone
Description: For intervention A: Once a patient is randomized to telephone (Intervention A), s/he will be scheduled for the series of follow up encounters via the assigned modality. The first interaction will occur within 72 hours of the patient receiving their prescribed OCA(s) at which time the standardized educational information regarding the agent(s), dosing of the medication and potential medication side effects will be reviewed with the patient and/or caregiver. The second through eighth encounters will take place every 2 weeks thereafter through the study timeframe up to four months to assess for adherence and toxicity. At each visit, an adherence assessment including pill count, and Oral Chemotherapy Adherence Scale (OCAS), fill history will be obtained prior to each interaction to verify medication possession ratio (MPR) and proportion of days covered (PDC). Each patient in the study will participate for a duration of up to 4 months.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention B- Televideo
Description: For intervention B: Once a patient is randomized to televideo (Intervention B), s/he will be scheduled for the series of follow up encounters via the assigned modality. The first interaction will occur within 72 hours of the patient receiving their prescribed OCA(s) at which time the standardized educational information regarding the agent(s), dosing of the medication and potential medication side effects will be reviewed with the patient and/or caregiver. The second through eighth encounters will take place every 2 weeks thereafter through the study timeframe up to four months to assess for adherence and toxicity. At each visit, an adherence assessment including pill count, and Oral Chemotherapy Adherence Scale (OCAS), fill history will be obtained prior to each interaction to verify medication possession ratio (MPR) and proportion of days covered (PDC). Each patient in the study will participate for a duration of up to 4 months.
Study: NCT06699511

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise
Study: NCT06699082

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KinesioTaping and Keltonborn Mobilization
Description: Experimental group was treated with kinesiotape and kaltenborn mobilization while the non experimental group was treated with conventional therapy along with kaltenborn mobilization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KinesioTaping and Keltonborn Mobilization
Description: Experimental group was treated with kinesiotape and kaltenborn mobilization while the non experimental group was treated with conventional therapy along with kaltenborn mobilization.
Study: NCT06698419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RADA16 gel application into mastoid cavity
Description: A single application of RADA16 gel will be applied along the surface of the mastoid cavity intraoperatively prior to insertion of gelatin sponge packing. Application will involve a thin layer of gel just enough to cover the entire surface of the cavity.
Study: NCT06699836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 350 mg leronlimab
Description: Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Study: NCT06179160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB161734
Description: INCB161734 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB161734
Description: INCB161734 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB161734
Description: INCB161734 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB161734
Description: INCB161734 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab will be administered at protocol defined dose.
Study: NCT06699836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 700 mg leronlimab
Description: Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Study: NCT06700200

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: taVNS
Description: transauricular vagus nerve stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: taVNS
Description: transauricular vagus nerve stimulation
Study: NCT06700187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interrupting sitting with walking breaks
Description: Participants will engage in 27 minutes walking in different frequencies, including short breaks (walk 1 minute every 10 minutes), moderate breaks (walk 3 minutes every 30 minutes), and long breaks (walk 27 minutes in one time during the intervention).
Study: NCT06698965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy （Etoposide and Carboplatin）
Description: Etoposide: 80-100mg/m2, Q3W, intravenous infusion is administered on day 1, 2 and 3 of each cycle.~Carboplatin: AUC=5, Q3W, intravenous infusion is administered on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy （Etoposide and Carboplatin）
Description: Etoposide: 80-100mg/m2, Q3W, intravenous infusion is administered on day 1, 2 and 3 of each cycle.~Carboplatin: AUC=5, Q3W, intravenous infusion is administered on day 1 of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy （Envafolimab）
Description: Envafolimab: 300mg, Q3W, subcutaneous injection is administered on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy （Envafolimab）
Description: Envafolimab: 300mg, Q3W, subcutaneous injection is administered on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Trilaciclib: 240mg/m2, Q3W, intravenous infusion should be completed within 4 hours before daily chemotherapy
Study: NCT06698822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib 2% cream
Description: Given topical
Study: NCT06698523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing exercise
Description: bubble blower used as play toys to facilitate the breathing exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deep breathing
Description: pin wheel used as a play toy for achievement of breathing exercise
Study: NCT06699550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haptonomy
Description: The session transitioned to energy work and dream visualization. The researcher and the pregnant participant placed their left hands on each other's hearts. The goal was for the participants to feel the energy flowing between them, sense their hearts, open their third eye, and prepare their hands. This exercise aimed to enhance the pregnant participant's confidence in her own emotions and body by recognizing her feelings and physical sensations. Next, the researcher and the pregnant participant placed their right hands on the participant's forehead and their left hands over their hearts. This positioning facilitated the pregnant participant in visually sensing the presence of her baby. It was intended to promote communication between the mother and her baby at both a physical and spiritual level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction Program
Description: Participants were introduced to each other and provided with information related to pregnancy. The Mindfulness-Based Stress Reduction Program (MBSR) was introduced. The participants shared their levels of well-being, stress, coping mechanisms for fear of childbirth, and their expectations from the MBSR program. Awareness of habitual behaviors was facilitated. Afterwards, breath-focused meditation and dried fruit meditation were practiced. Participants were encouraged to maintain awareness of activities performed at any time during the day. Lastly, body scan meditation was taught, and participants were instructed to repeat the practice throughout the week using audio recordings.
Study: NCT06698471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community worker training
Description: Training community workers in Self Help Plus intervention, a 5 session self-help intervention based on Acceptance and Commitment Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral to Health System
Description: Referral to Health System of Senegal
Study: NCT06700083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6934 injection
Description: SHR-6934 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6934 injection
Description: SHR-6934 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6934 injection
Description: SHR-6934 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6934 injection
Description: SHR-6934 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6934 injection
Description: SHR-6934 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6934 injection
Description: SHR-6934 injection
Study: NCT06416358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALMB-0168
Description: ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
Study: NCT06414135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relma-cel
Description: All participants will receive Relma-cel once at different dose levels: 25×10\^6 CAR+ T cells、50×10\^6 CAR+ T cells、75×10\^6 CAR+ T cells
Study: NCT06170463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: Met Group Received metformin hydrochloride 500 mg tab 3 times Daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MI/DCI combination in 40:1 ratio
Description: MI-group received MI/DCI combination in 40:1 ratio twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination of Metformin hydrochloride and MI/DCI
Description: MM Group Received both Met and MI Groups Treatment
Study: NCT06090981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bovine surfactant
Description: Dose of surfactant: 4ml/kg Type of surfactant: 4ml/kg
Study: NCT06179160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMNabP
Description: GEMNabP will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMNabP
Description: GEMNabP will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX will be administered at protocol defined dose.
Study: NCT05719441

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: 10 mg/kg intravenous infusion over approximately 15 to 30 minutes once at entry

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: 5 mg/kg intravenous infusion over approximately 30 to 60 minutes once at entry

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection USP, 0.9%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART
Description: Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet orally once daily with or without food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ART
Description: Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet orally once daily with or without food
Study: NCT06139796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV/r FDC (120/20mg)
Description: Initiation of DRV/r FDC (120/20mg) as part of antiretroviral therapy (ART) with an Optimized Background Therapy (OBT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV/r FDC (120/20mg)
Description: Initiation of DRV/r FDC (120/20mg) as part of antiretroviral therapy (ART) with an Optimized Background Therapy (OBT)
Study: NCT05596162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Therapy
Description: Exercise with Blood Flow Restriction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy
Description: Exercise without Blood Flow Restriction
Study: NCT06700083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6934 injection
Description: SHR-6934 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6934 injection
Description: SHR-6934 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6934 injection
Description: SHR-6934 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6934 injection
Description: SHR-6934 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6934 placebo
Description: SHR-6934 placebo
Study: NCT04530123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-101 placebo-matching intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-101 placebo-matching intravenous infusion
Study: NCT06700083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6934 placebo
Description: SHR-6934 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6934 placebo
Description: SHR-6934 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6934 placebo
Description: SHR-6934 placebo
Study: NCT06655298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: US guided block
Description: Group Q; (28 patients) Quadratus lumborum block group; patients will receive general anesthesia initially then bilateral QLB type III (anterior subcoastal approach) with a volume of 30 mL of bupivacaine 0.25% for each side taking care that the patient does not receive a local anesthetic dose higher than the maximum allowed (2.5 mg/kg) \[9\].~✓ Group E; (28 patients) Erector spinae plane block; patients will receive general anesthesia initially then bilateral ESPB with a volume of 30 mL of bupivacaine 0.25 % for each side taking care that the patient does not receive a local anesthetic dose higher than the maximum allowed (2.5 mg/kg
Study: NCT04530123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-101
Description: TAK 101 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-101
Description: TAK 101 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-101
Description: TAK 101 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-101
Description: TAK 101 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-101
Description: TAK 101 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-101
Description: TAK 101 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-101
Description: TAK 101 intravenous infusion

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten
Description: Powder form (vital wheat gluten)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten
Description: Powder form (vital wheat gluten)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten
Description: Powder form (vital wheat gluten)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten
Description: Powder form (vital wheat gluten)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten
Description: Powder form (vital wheat gluten)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten
Description: Powder form (vital wheat gluten)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten
Description: Powder form (vital wheat gluten)
Study: NCT06526364

Intervention type: OTHER
Intervention: All participants will be asked to provide data and samples for collection and analysis.
Description: During the first year, data related to demographics, lifestyle, clinical examinations will be collected at baseline, at 6 months (optional) and at 12 months. PROs, cognitive and motor assessments will be performed using the Healios+Me smartphone app. Additionally, participants will be asked to provide biological samples (i.e., blood, cerebrospinal fluid and stool, saliva and hair) and imaging data (if performed as per standard of care). One unscheduled visit may be performed in case the participant comes to the hospital with the occurrence of flare or for a treatment change.~A long-term follow-up (FU, starting from month 12 and up to 4 years after month 12) is foreseen in this study. During the long-term FU medical data are collected either every 6 month or on a yearly basis, and PROs are collected every 6 months. Whether study visits are conducted in 6- or 12-monthly intervals depends on the schedule of the study visits for the Swiss MS cohort (SMSC).
Study: NCT05082909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probenecid
Description: Addition of 500mg QDS to oral penicillin.
Study: NCT06700083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6934 placebo
Description: SHR-6934 placebo
Study: NCT06778304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal F
Description: The reference formulation is the recombinant human follicle-stimulating hormone injection (Gonal-f®) originally developed and produced by Merck Serono

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: jzb30
Description: The test formulation is the recombinant human follicle-stimulating hormone injection (code: JZB30) produced by Shanghai Jingze Biotechnology Co., Ltd./Chengdu Jingze Biopharmaceutical Co., Ltd.
Study: NCT06777940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kegel exercises
Description: It consists of 25 patients who will receive Kegel exercises with Myokinetic active release of trigger points in quadratus lumborum, rectus abdominis and gluteus medius. Patient will be in lying position with empty bladder. Ask patient to tight pelvic floor muscle group and hold tight from 3-5 seconds Then relax muscle group from 3-5 seconds with Myokinetic therapy targeted at releasing muscle of quadratus lumborum, rectus abdominis and gluteus medius release was applied passively by sustained pressure for 8-10 seconds. This protocol consisted of three sets with 2 minutes of rest..Participants will be asked to perform exercise 30 times each session following hold and relax of muscle group for 3-5 seconds
Study: NCT06779110

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Using OCT to guide PCI in ISR

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Using OCT to guide PCI in ISR
Study: NCT06779006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help acceptance and commitment therapy with behavioral activation
Description: Internet-based self-help acceptance and commitment therapy with behavioral activation
Study: NCT06778070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor yoga
Description: Pelvic floor yoga

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical conditioning
Description: Physical conditioning
Study: NCT06778993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding Education Program Accompanied by a Wearable (Hybrid) Simulator
Description: This training is conducted in both theoretical and practical formats. The theoretical training consists of two sessions, each lasting 25 minutes, with a 10-minute break in between, totaling 60 minutes. Following the theoretical training, simulation-based skill training is conducted. This phase also comprises two sessions of 25 minutes each, with a 10-minute break, making a total duration of 60 minutes.
Study: NCT06778278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Health and Resilience through Valued Experiences (THRiVE) Program
Description: Six (6) total weekly, 90-minute, small-group, peer-led sessions delivered virtually
Study: NCT06779045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK-1286
Description: Cohort 1: 1 mg/d QD AK-1286 PO,DLT observation period: 21 days. Cohort 2: 2 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 3: 4 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 4: 5 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 5: 16 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 6: 24 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 7: 36 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 8: 50 mg/d BID AK-1286 PO,DLT observation period: 21 days.
Study: NCT06779084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: contemporary fasting principle
Description: (clear fluids for up to 2 hours before anesthesia)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional fasting time
Description: (≥ 8 hours)